Valuation: Genmab

Market Cap 117B 17.89B 15.63B 14.45B 13.35B 25.14B 1,718B 25.59B 172B 67.61B 841B 67.18B 65.7B 2,897B P/E 2026 *
25.1x
P/E 2027 * 17.4x
Enterprise Value 136B 20.84B 18.21B 16.83B 15.55B 29.29B 2,001B 29.82B 201B 78.76B 980B 78.26B 76.53B 3,374B EV / Sales 2026 *
4.86x
EV / Sales 2027 * 3.91x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
+53.20%+4.14% - - 17.82B
+6.05%+3.69%+65.28%+89.94% 53.54B
+0.21%-6.28%+56.18%+127.90% 54.18B
+0.97%-2.04%+8.49%+436.60% 23.66B
+0.50%-3.99%-18.44%-16.36% 22.78B
+2.36%+1.06%+43.34%-6.14% 19.54B
-4.00%-7.88%+175.60%+343.60% 16.01B
-1.15%-4.83%+46.53%+627.30% 15.37B
-0.33%-2.15%+22.53%+188.04% 14.09B
+0.36%-2.24%+66.68%+136.15% 12.24B
Average +0.48%-1.90%+51.80%+214.11% 25.71B
Weighted average by Cap. +1.33%-0.78%+51.11%+177.35%

Financials

2026 *2027 *
Net sales 28.01B 4.29B 3.75B 3.46B 3.2B 6.03B 412B 6.13B 41.3B 16.2B 202B 16.1B 15.75B 694B 32.88B 5.03B 4.4B 4.07B 3.76B 7.07B 483B 7.2B 48.48B 19.02B 237B 18.9B 18.49B 815B
Net income 4.71B 721M 630M 582M 538M 1.01B 69.24B 1.03B 6.95B 2.72B 33.91B 2.71B 2.65B 117B 7.06B 1.08B 944M 873M 807M 1.52B 104B 1.55B 10.41B 4.08B 50.83B 4.06B 3.97B 175B
Net Debt 19.27B 2.95B 2.58B 2.38B 2.2B 4.15B 283B 4.22B 28.42B 11.15B 139B 11.08B 10.84B 478B 11.76B 1.8B 1.57B 1.45B 1.34B 2.53B 173B 2.58B 17.34B 6.8B 84.65B 6.76B 6.61B 291B
Logo Genmab
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A